Similar articles

• Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?

  Carlsson A. Carlsson A. J Neural Transm Suppl. 1983;19:153-61. J Neural Transm Suppl. 1983. PMID: 6321646
• [Medicinal treatment of idiopathic Parkinson's disease].

  Klockgether T. Klockgether T. Nervenarzt. 2003 Mar;74 Suppl 1:S12-21. doi: 10.1007/s00115-003-1483-8. Nervenarzt. 2003. PMID: 12624679 German.
• The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?

  Agid Y, Graybiel AM, Ruberg M, Hirsch E, Blin J, Dubois B, Javoy-Agid F. Agid Y, et al. Adv Neurol. 1990;53:83-100. Adv Neurol. 1990. PMID: 1978522 Review. No abstract available.
• In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.

  Brannan T, Knott P, Kaufmann H, Yahr M. Brannan T, et al. Adv Neurol. 1990;53:75-81. Adv Neurol. 1990. PMID: 2173378 No abstract available.
• Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.

  Knoll J. Knoll J. Adv Neurol. 1990;53:425-9. Adv Neurol. 1990. PMID: 2122648 Review. No abstract available.